Palbociclib for Breast Cancer: 37 Real Stories

37 stories match breast cancer and palbociclib. 35 of them mention targeted therapy.

Cancer Stories

Kate, who was diagnosed with Stage IV Breast CancerBreast Cancer

Kate's Story: How I Lean Into Every Day With MBC

Patient Info: Kate | Stage IV

Biomarkers: ER-positive, HER2-negative

Metastatic Site: liver

7+ years living with de novo metastatic ER-positive, HER2-negative breast cancer with liver metastases while remaining on first-line palbociclib and letrozole.

breastcancer.org
OutcomeLiving With Cancer
Kattysmith, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Kattysmith's Patient Story

Patient Info: Kattysmith, Female, 60s | Stage IV

Metastatic Site: lymphatic system; skin/soft-tissue nodules; possible…

After AC chemotherapy, the metastatic nodules shrank markedly. Kattysmith was stable on palbociclib and letrozole with declining tumor markers, while clearly stating that she was not NED.

breastcancer.org
OutcomeResponding Well
SH
Breast Cancer

Sarah: hormone-dependent grade 1 breast cancer with individualized treatment decisions

Patient Info: Sarah, Female, 50s

Biomarkers: Hormone-dependent

Sarah’s June 2020 MRI showed that previously visible breast nodules were no longer present after metabolic measures and an oncologist-prescribed regimen including hormone suppression, cyclophosphamide, and palbociclib.

Cancer et Métabolisme
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Hidden metastatic breast cancer found in bone marrow during blood-cancer monitoring

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive

Metastatic Site: bone marrow, bone

More than 7 years after metastatic breast carcinoma was first identified in 2018, she had stable skeletal disease and ongoing biochemical improvement on palbociclib plus fulvestrant in March 2026.

PubMed Central
OutcomeStable Disease
Bethany, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage IV

Metastatic Site: Bones; liver; lymph nodes; stomach

As of June 2026, Bethany was living with Stage IV metastatic breast cancer and responding well to maintenance treatment, with scans described as phenomenal and disease areas shrinking or disappearing.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV ER-positive/HER2-negative breast cancer with synchronous gastric and bone metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Gastric metastasis showed ER-positive, PR-negative, HER2 0 lobular breast cancer. Breast primary was ER/PR-positive, HER2-negative

Metastatic Site: bone; stomach/gastric

At 2-month follow-up, upper-GI symptoms had improved, anastrozole plus palbociclib was tolerated, and CT showed stable disease with persistent diffuse osseous metastases; no further follow-up was available.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed Central
OutcomeResponding Well
Dalitso, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV Invasive Ductal Carcinoma: Dalitso's Patient Story

Patient Info: Dalitso, Female, Under 40 | Stage IV

Metastatic Site: bone: spine, ribs, sternum, hip sockets

Dalitso had severe Stage IV bone-metastatic breast cancer with hospice-level symptoms and later bone progression, but subsequent imaging after a new treatment approach showed no visible active disease.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed Central
OutcomeLiving With Cancer
Lourdes, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Lourdes's Patient Story

Patient Info: Lourdes Monje, Under 40 | Stage IV

Metastatic Site: lung

Lourdes is receiving investigational treatment through a clinical trial, with manageable side effects, while continuing to work and spend time with family and friends.

AACR
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: complete remission with letrozole and palbociclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Breast cancer was ER/PR positive, HER2 0

Metastatic Site: pleura/pleural effusion

Breast cancer remained in remission on letrozole after palbociclib was stopped; Ph-positive B-ALL achieved complete response with no molecular residual disease after blinatumomab plus ponatinib, with ongoing monthly outpatient monitoring.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed Central
OutcomeLiving With Cancer
Lisa, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Lisa's Patient Story

Patient Info: Lisa Ordmandy, Female, 60s | Stage IV

Metastatic Site: Spine/bone: C2 and L3 vertebrae

As of June 2024, Lisa was living with metastatic breast cancer as a chronic illness, had recovered mobility after November 2023 spine surgery, continued close MD Anderson monitoring, and was being evaluated for possible clinical trials.

MD Anderson
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed Central
OutcomeCare Ongoing